Status:
WITHDRAWN
Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Age Matched Healthy Volunteers (Non-smokers)
Eligibility:
All Genders
40-75 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to compare histone acetyltransferase (HAT) and histone deacetylase (HDAC) expressions and activities in induced sputum macrophages obtained from patients with moderate to s...
Eligibility Criteria
Inclusion
- Inclusion Criteria-Healthy non-smokers
- Non-smoking volunteer
- aged 40 -75 years (age matched to COPD patients)
- Normal spirometry (normal FEV1/FVC ratio \>70% and FEV1\>80% predicted)
- Subjects are able to give informed consent
- Inclusion Criteria-COPD patients (stage II-III according to the GOLD guidelines)
- Current and/or ex-smokers with no less than 10 pack-year smoking history
- aged 40 -75 years
- FEV1 greater than or equal to 30% and less than 80% of predicted (the upper value is a prostbronchodilator value)
- FEV1/FVC \< 70%
- Patients with stable COPD
- Inhaled Corticosteroid (ICS) treatment, if exists, must be stopped for 2 weeks prior the study treatment
- Long-acting beta2-agonists and theophylline need to be stopped at least 3 days before run-in , but anti-cholinergics will be allowed throughout the study
- The subjects are able to give informed consent
Exclusion
- Exclusion Criteria-Healthy non-smokers
- Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator
- Upper respiratory infection within the last 4 weeks
- Subjects who have received research medication within the previous one month
- Subjects unable to give informed consent
- Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
- Exclusion Criteria-COPD patients
- Evidence of asthma
- Bronchodilator reversibility \> 12%
- Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator
- Patients who have had oral steroids within 8 weeks prior to the screening visit.
- Patients who are already on ICS and in which it is considered unsafe (as judged by the Investigator) to stop this treatment for the study period.
- Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the screening visit.
- Upper respiratory infection within the last 4 weeks
- Subjects who have received research medication within the previous one month
- Subjects unable to give informed consent
- Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study
- Patients with significant co-morbidities as judged by the investigator
- Any other respiratory disease, which is considered by the investigator to be clinically significant
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00291408
Start Date
April 1 2006
End Date
June 1 2007
Last Update
August 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY